ADMA Biologics, Inc. (ADMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.62+0.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ADMA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | 512.3 | 510.2 | 426.5 | 258.2 | 154.1 | 80.9 | 42.2 | 29.3 | 17.0 | 22.8 | 10.7 | 7.2 | 5.9 | 3.1 | 1.1 |
| Total Revenues | — | — | — | — | — | — | 42.2 | 29.3 | 17.0 | 22.8 | 10.7 | 7.2 | 5.9 | 3.1 | 1.1 |
| Cost of Revenues | 180.8 | 217.4 | 206.9 | 169.3 | 118.8 | 79.8 | 61.3 | 39.5 | 42.2 | 29.2 | — | — | — | — | — |
| Gross Profit | 331.5 | 292.8 | 219.6 | 88.9 | 35.3 | 1.2 | (19.1) | — | (25.2) | (6.4) | 4.3 | 2.9 | 2.2 | 1.0 | 0.4 |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | 98.8 | 91.6 | 74.1 | 59.0 | 52.5 | 42.9 | 35.1 | — | — | — | — | — | — | — | — |
| R&D Expenses | 11.5 | 4.8 | 1.8 | 3.3 | 3.6 | 3.6 | 5.9 | 2.3 | 3.9 | 5.6 | 7.7 | 7.0 | 9.5 | 9.3 | 3.5 |
| Operating Income | 224.5 | 191.4 | 139.0 | 21.6 | (39.4) | (58.4) | (64.9) | (41.4) | (60.3) | (39.3) | (17.3) | (15.5) | (16.0) | (15.0) | (7.9) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | 7.1 | 13.9 | 25.0 | 19.3 | 13.1 | 12.0 | 9.0 | 5.5 | 3.3 | 2.2 | 1.8 | 1.3 | 0.6 | 0.0 |
| Interest & Investment Income | — | 1.9 | 2.1 | 1.6 | 0.0 | 0.0 | 0.3 | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | 23.4 | 19.2 | 13.0 | 11.7 | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (8.0) | (8.8) | (13.3) | (49.9) | (26.5) | (13.3) | (10.8) | (6.9) | (5.5) | (4.4) | (2.2) | (2.5) | (1.3) | (0.5) | — |
| Asset Writedown | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.8 | — | — | — | — | — |
| EBT, Incl. Unusual Items | 216.5 | 182.7 | 125.7 | (28.2) | (65.9) | — | — | — | — | — | (19.5) | (18.0) | (17.4) | (15.5) | (7.9) |
| Income Tax Expense | 47.5 | 35.7 | (72.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.6) | 0.0 | — |
| Net Income | |||||||||||||||
| Net Income | 169.0 | 146.9 | 197.7 | (28.2) | (65.9) | (71.7) | (75.7) | (48.3) | (65.7) | (43.8) | (19.5) | (18.0) | (16.8) | (15.5) | (7.3) |
| Per Share | |||||||||||||||
| Basic EPS | 0.74 | 0.62 | 0.85 | (0.13) | (0.33) | (0.51) | (0.88) | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.73 | 0.60 | 0.81 | (0.13) | (0.33) | (0.51) | (0.88) | — | — | — | — | — | — | — | — |
| Revenue per Share | 2.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 228.2 | 238.3 | 233.1 | 224.0 | 197.9 | 139.6 | 86.1 | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 230.3 | 244.9 | 243.3 | 224.0 | 197.9 | 139.6 | 86.1 | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | 199.5 | 147.0 | 30.0 | (32.3) | (52.9) | (61.0) | (38.2) | (56.8) | (36.6) | (16.9) | (15.0) | (15.8) | (14.8) | (7.7) |
| EBIT | 224.5 | 191.4 | 139.0 | 21.6 | (39.4) | (58.4) | (64.9) | (41.4) | (60.3) | (39.3) | (17.3) | (15.5) | (16.0) | (15.0) | (7.9) |
| Effective Tax Rate | 22.0% | — | — | 0.0% | 0.0% | — | — | — | — | — | 0.0% | 0.0% | 3.2% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.